Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 172,916,816
  • Shares Outstanding, K 2,735,160
  • Annual Sales, $ 39,807 M
  • Annual Income, $ 3,920 M
  • 36-Month Beta 0.80
  • Price/Sales 4.35
  • Price/Cash Flow 10.93
  • Price/Book 4.36

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.88 +0.54%
on 10/17/17
66.41 -4.80%
on 09/18/17
-2.94 (-4.44%)
since 09/15/17
3-Month
61.16 +3.37%
on 08/18/17
66.41 -4.80%
on 09/18/17
+0.61 (+0.97%)
since 07/17/17
52-Week
58.29 +8.46%
on 11/03/16
66.80 -5.36%
on 03/01/17
+1.70 (+2.76%)
since 10/17/16

Most Recent Stories

More News
J&J (JNJ) Beats on Q3 Earnings, Actelion Buyout Drives Sales

J&J (JNJ) reported better-than-expected third-quarter 2017 results and raised its 2017 sales and profit outlook.

JNJ : 140.79 (+3.43%)
MRK : 63.22 (-0.19%)
ABBV : 92.17 (+1.24%)
PFE : 36.20 (+0.61%)
Bristol-Myers Gets Priority Review for Opdivo Label Expansion

Bristol-Myers (BMY) announced that that the FDA has accepted the supplemental Biologics License Application for priority review of Opdivo to treat patients with melanoma.

AZN : 34.78 (+0.38%)
NVO : 49.31 (-0.02%)
MRK : 63.22 (-0.19%)
BMY : 64.18 (+0.83%)
Corbus Pharmaceuticals Appoints Paris Panayiotopoulos to Its Board of Directors

NORWOOD, MA--(Marketwired - October 17, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious...

CRBP : 7.05 (+2.17%)
DNPUF : 13.6000 (+4.62%)
ARIA : 23.99 (+0.17%)
MRK : 63.22 (-0.19%)
MDCO : 34.57 (-0.89%)
LLY : 86.06 (+0.13%)
MTZPY : 22.7100 (-0.70%)
BMY : 64.18 (+0.83%)
MKKGY : 22.3800 (-1.62%)
Corbus Pharmaceuticals Appoints Paris Panayiotopoulos to Its Board of Directors

NORWOOD, MA--(Marketwired - October 17, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious...

CRBP : 7.05 (+2.17%)
DNPUF : 13.6000 (+4.62%)
ARIA : 23.99 (+0.17%)
MRK : 63.22 (-0.19%)
MDCO : 34.57 (-0.89%)
LLY : 86.06 (+0.13%)
MTZPY : 22.7100 (-0.70%)
BMY : 64.18 (+0.83%)
MKKGY : 22.3800 (-1.62%)
Cancer Space Update: Lung & Breast Cancer Studies in Focus

While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.

AZN : 34.78 (+0.38%)
MRK : 63.22 (-0.19%)
LLY : 86.06 (+0.13%)
CLVS : 81.32 (-3.85%)
ABBV : 92.17 (+1.24%)
SGEN : 64.08 (+1.89%)
Pharma Stock Roundup: Pfizer Mulls Options for Consumer Healthcare, LLY's Pipeline Setback

Pfizer (PFE) is looking at strategic options for its Consumer Healthcare business while Merck announced that it won't be seeking approval for its CETP inhibitor.

AERI : 64.60 (+0.86%)
ACRX : 1.75 (-10.26%)
MRK : 63.22 (-0.19%)
LLY : 86.06 (+0.13%)
AGN : 197.78 (-0.32%)
PFE : 36.20 (+0.61%)
BMY : 64.18 (+0.83%)
Pneumonia Drug Development Pipeline Review, 2017

SummaryCommunity acquired pneumonia refers to pneumonia contracted by a person who has had little contact with the healthcare system. There are a total of 20 products in development for this indication,...

MRK : 63.22 (-0.19%)
Mirati Therapeutics' Mocetinostat Included In Stand Up To Cancer's Cutting-Edge Clinical Trial Initiative For NSCLC Patients

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage oncology biotechnology company, announced today that the Company has been included in the SU2C CatalystTM program, a cutting-edge research initiative...

MRK : 63.22 (-0.19%)
MRTX : 14.25 (+4.01%)
Merck Will Not Seek Approval for CETP Inhibitor Anacetrapib

Merck (MRK) is not seeking approval for its CETP inhibitor anacetrapib, which it had developed for cholesterol management.

MRK : 63.22 (-0.19%)
LLY : 86.06 (+0.13%)
RHHBY : 31.4500 (+0.87%)
PFE : 36.20 (+0.61%)
Merck Makes $3 Million Charitable Donation to Support Swim Across America

--Merck Employees to Conduct Their Own "Swim Across America" Starting in 2018

MRK : 63.22 (-0.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines...

See More

Support & Resistance

2nd Resistance Point 63.57
1st Resistance Point 63.39
Last Price 63.22
1st Support Level 62.96
2nd Support Level 62.71

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart